STOCK TITAN

[Form 4] KORU Medical Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share. Following the transaction the reporting person beneficially owned 41,688 shares. The filing is a Form 4 statement of changes in beneficial ownership and was signed by Thomas Adams as attorney-in-fact.

Edward Wholihan, direttore di KORU Medical Systems, Inc. (KRMD), ha riferito un'acquisto di 3.916 azioni ordinarie della società il 10/02/2025 al prezzo di $3,83 per azione. Dopo l'operazione la persona che riporta i dati possedeva 41.688 azioni. Il fascicolo è una dichiarazione Form 4 sui cambiamenti nella titolarità beneficiaria ed è stata firmata da Thomas Adams come procuratore ad acta.

Edward Wholihan, director de KORU Medical Systems, Inc. (KRMD), informó una compra de 3.916 acciones de las acciones comunes de la compañía el 02/10/2025 a un precio de $3,83 por acción. Tras la transacción, la persona reportante poseía 41.688 acciones. El archivo es una declaración Form 4 de cambios en la titularidad beneficiosa y fue firmado por Thomas Adams como apoderado legal.

Edward Wholihan, KORU Medical Systems, Inc. (KRMD)이사로서 10/02/2025에 회사의 보통주를 3,916주 매수했다고 보고했습니다. 주당 가격은 $3.83였으며 거래 후 보고인은 41,688주를 실질적으로 보유하게 되었습니다. 이 제출 서류는 수익 소유 변경에 대한 Form 4 진술이며, Thomas Adams를 대리인으로 하여 서명되었습니다.

Edward Wholihan, directeur de KORU Medical Systems, Inc. (KRMD), a rapporté l'achat de 3 916 actions ordinaires de la société le 10/02/2025 au prix de $3,83 par action. Suite à la transaction, la personne déclarant détenait 41 688 actions. Le dépôt est une déclaration Form 4 de changements dans la titularisation bénéficiaire et a été signée par Thomas Adams en tant qu'administrateur de fait.

Edward Wholihan, ein Direktor von KORU Medical Systems, Inc. (KRMD), meldete den Kauf von 3.916 Stammaktien des Unternehmens am 02.10.2025 zu einem Preis von 3,83 $ pro Aktie. Nach der Transaktion besaß die meldende Person rechtlich 41.688 Aktien. Die Einreichung ist eine Form 4-Erklärung zu Veränderungen im begünstigten Eigentum und wurde von Thomas Adams als Bevollmächtigter unterzeichnet.

Edward Wholihan، مدير في KORU Medical Systems, Inc. (KRMD)، أبلغ عن شراء 3,916 سهماً من أسهم الشركة العادية في تاريخ 10/02/2025 بسعر $3.83 للسهم. بعد الصفقة، امتلك الشخص المبلغ عنه فعلياً 41,688 سهماً. هذا التقديم هو بيان Form 4 للتغيرات في الملكية المستفيدة، وتم توقيعه من قِبل Thomas Adams كوكيل قانوني.

Edward Wholihan,KORU Medical Systems, Inc. (KRMD)董事,报告于2025/10/02以每股$3.83购买公司普通股共3,916股。交易后,申报人实际持有的股份为41,688股。该申报为

形态Form 4
的受益所有权变动声明,由Thomas Adams先生作为代签人签署。

Positive
  • Director purchase of 3,916 shares reported, increasing insider holdings
  • Transaction price disclosed: $3.83, providing a precise cost basis for the purchase
  • Post-transaction beneficial ownership: 41,688 shares clearly stated
Negative
  • None.

Edward Wholihan, direttore di KORU Medical Systems, Inc. (KRMD), ha riferito un'acquisto di 3.916 azioni ordinarie della società il 10/02/2025 al prezzo di $3,83 per azione. Dopo l'operazione la persona che riporta i dati possedeva 41.688 azioni. Il fascicolo è una dichiarazione Form 4 sui cambiamenti nella titolarità beneficiaria ed è stata firmata da Thomas Adams come procuratore ad acta.

Edward Wholihan, director de KORU Medical Systems, Inc. (KRMD), informó una compra de 3.916 acciones de las acciones comunes de la compañía el 02/10/2025 a un precio de $3,83 por acción. Tras la transacción, la persona reportante poseía 41.688 acciones. El archivo es una declaración Form 4 de cambios en la titularidad beneficiosa y fue firmado por Thomas Adams como apoderado legal.

Edward Wholihan, KORU Medical Systems, Inc. (KRMD)이사로서 10/02/2025에 회사의 보통주를 3,916주 매수했다고 보고했습니다. 주당 가격은 $3.83였으며 거래 후 보고인은 41,688주를 실질적으로 보유하게 되었습니다. 이 제출 서류는 수익 소유 변경에 대한 Form 4 진술이며, Thomas Adams를 대리인으로 하여 서명되었습니다.

Edward Wholihan, directeur de KORU Medical Systems, Inc. (KRMD), a rapporté l'achat de 3 916 actions ordinaires de la société le 10/02/2025 au prix de $3,83 par action. Suite à la transaction, la personne déclarant détenait 41 688 actions. Le dépôt est une déclaration Form 4 de changements dans la titularisation bénéficiaire et a été signée par Thomas Adams en tant qu'administrateur de fait.

Edward Wholihan, ein Direktor von KORU Medical Systems, Inc. (KRMD), meldete den Kauf von 3.916 Stammaktien des Unternehmens am 02.10.2025 zu einem Preis von 3,83 $ pro Aktie. Nach der Transaktion besaß die meldende Person rechtlich 41.688 Aktien. Die Einreichung ist eine Form 4-Erklärung zu Veränderungen im begünstigten Eigentum und wurde von Thomas Adams als Bevollmächtigter unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
WHOLIHAN EDWARD

(Last) (First) (Middle)
C/O KORU MEDICAL SYSTEMS, INC.
100 CORPORATE DRIVE

(Street)
MAHWAH NJ 07430

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 A 3,916 A $3.83 41,688 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.
/s/ Thomas Adams- Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did KRMD director Edward Wholihan report?

He reported the purchase of 3,916 shares of KORU Medical Systems common stock on 10/02/2025.

At what price were the KRMD shares purchased in the Form 4?

The reported purchase price was $3.83 per share.

How many KRMD shares does the reporting person own after the transaction?

The Form 4 shows beneficial ownership of 41,688 shares following the reported transaction.

Who signed the Form 4 filing for Edward Wholihan?

The filing bears the signature of Thomas Adams as Attorney-in-Fact dated 10/02/2025.

What type of SEC form was filed for this insider transaction?

A Form 4 (Statement of Changes in Beneficial Ownership) was filed pursuant to Section 16.
Koru Med Sys

NASDAQ:KRMD

KRMD Rankings

KRMD Latest News

KRMD Latest SEC Filings

KRMD Stock Data

181.70M
42.38M
8.29%
55.73%
2.53%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MAHWAH